Frontotemporal dementia (FTD) has a stronger genetic component than most other forms of dementia. Up to 40% of people with FTD have a family history of the disease, and roughly 15% to 40% of all cases are caused by a single gene mutation. The remaining cases appear to occur sporadically, with no clear inherited cause. So the short answer is: FTD is not always genetic, but it is genetic more often than conditions like Alzheimer’s disease.
How Often FTD Runs in Families
Studies consistently show that about one-third of FTD patients have a family history suggesting autosomal dominant inheritance, meaning the disease passes directly from parent to child. In one large Italian cohort of 570 FTD patients, 123 (roughly 22%) were classified as familial. Other research places the number higher, with a positive family history in as many as 60% of cases when more distant relatives are included.
Not every familial case has an identifiable gene mutation. Some families have a clear pattern of disease across generations but no mutation that current testing can detect. And some people with a known FTD-causing mutation have no family history at all, likely because their relatives died of other causes before symptoms appeared or because the mutation arose spontaneously.
The Three Major Genes Involved
Three genes account for the vast majority of genetic FTD, together explaining about 70% of all familial cases and 10% to 20% of all FTD cases combined.
- C9orf72: The most common genetic cause. This mutation involves an abnormal repeat of a short DNA sequence on chromosome 9. It was found in about 7% of all FTD cases in one large study, rising to roughly 13.5% among familial cases. C9orf72 mutations also overlap significantly with ALS (amyotrophic lateral sclerosis), so some carriers develop motor neuron disease alongside or instead of dementia.
- GRN (progranulin): Mutations in this gene cause the brain to produce insufficient progranulin, a protein essential for cellular cleanup and recycling processes. GRN mutations were found in about 3% of familial FTD cases. Over time, progranulin deficiency leads to toxic buildup in brain cells and neuroinflammation.
- MAPT (tau): This gene provides instructions for making the tau protein, which helps stabilize the internal structure of brain cells. When mutated, tau misfolds and accumulates. MAPT mutations vary significantly by population and geography. Some study populations show virtually no MAPT mutations, while others show higher rates.
A handful of rarer genes also contribute. Mutations in a gene called VCP can cause FTD alongside a bone condition called Paget disease and a type of muscle disease. Another rare gene, CHMP2B, has been identified in a small number of families. These account for a tiny fraction of cases but matter for families who test negative for the three major genes yet still show a strong inheritance pattern.
How Genetic FTD Is Inherited
Familial FTD follows an autosomal dominant pattern. If a parent carries a disease-causing mutation, each child has a 50% chance of inheriting it. The mutation is not sex-linked, so it passes equally from mothers and fathers to sons and daughters.
Carrying the mutation does not guarantee you will develop symptoms at a specific age. Penetrance, the likelihood that a mutation carrier actually develops the disease, increases with age. Research tracking 17 multigenerational families found penetrance of about 28% by age 40, 52% by age 50, 75% by age 60, 88% by age 70, and essentially 100% by age 80. In practical terms, this means a younger mutation carrier may live decades before symptoms begin, but the probability climbs steeply through middle age and beyond.
What Genetic Testing Looks Like
Current guidelines recommend that genetic counseling and comprehensive testing be offered to all FTD patients, regardless of whether they have a known family history. This is partly because family history can be incomplete or misleading. A parent might have died young, been misdiagnosed with a psychiatric condition, or simply never been evaluated.
For people who already have FTD symptoms, testing can identify the specific mutation driving the disease, which increasingly matters for treatment options. For at-risk family members without symptoms, the decision is more complex. Pre-symptomatic testing typically involves a structured counseling process before any blood is drawn. Counselors walk through what a positive or negative result would mean practically and emotionally.
The psychological stakes are real. People who learn they carry a mutation may experience emotional burden, hypervigilance about normal forgetfulness, and shifts in how they see themselves. Others report a sense of relief, feeling that knowing allows them to plan rather than live in uncertainty. The responses vary enormously between individuals, which is why the counseling step exists.
Does the Gene Affect How the Disease Progresses?
The specific mutation a person carries can shape the type of symptoms they develop and when those symptoms begin. C9orf72 carriers, for example, are more likely to develop a mix of behavioral changes and motor neuron symptoms, sometimes resembling ALS. GRN mutation carriers tend to present with language difficulties or asymmetric brain atrophy, where one side of the brain is more affected than the other. MAPT mutations more often cause the classic behavioral variant, with personality changes and impaired social judgment appearing first.
Age of onset also varies by gene. MAPT mutations tend to cause earlier symptoms, sometimes in the 40s or even late 30s. GRN and C9orf72 mutations have wider ranges, with onset typically between the 50s and 70s. These are averages, though. Even within the same family carrying the same mutation, one person might develop symptoms at 45 and a sibling at 65.
Gene-Targeted Treatments in Development
The strong genetic basis of many FTD cases has opened the door to therapies that target the root cause rather than just managing symptoms. The most advanced work focuses on GRN mutations. Because the problem is insufficient progranulin protein, the therapeutic logic is straightforward: restore progranulin levels in the brain.
One approach uses a viral vector to deliver working copies of the GRN gene directly into the central nervous system through a single injection at the base of the skull. A phase 1/2 clinical trial (NCT04408625) has shown this gene therapy to be generally safe and well tolerated in early results. Other programs are testing antibodies that prevent progranulin from being broken down too quickly, effectively raising its levels through a different mechanism.
For C9orf72 carriers, therapies in development aim to silence the toxic RNA produced by the expanded repeat sequence. These are earlier in the pipeline but represent a fundamentally different kind of treatment than anything previously available for dementia. None of these therapies are approved yet, but they underscore why genetic testing matters: knowing your mutation type may determine which clinical trials or future treatments apply to you.